This article first appeared on GuruFocus .
Release Date: May 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Hyperfine Inc ( NASDAQ:HYPR ) reported a significant revenue increase of 83% year-over-year, reaching $3.9 million for Q1 2026.
-
The company achieved a gross margin of 51%, marking the third consecutive quarter with margins exceeding 50%.
-
Hyperfine Inc ( NASDAQ:HYPR ) obtained CE and UKCA marks for its next-generation subsystem and advanced DWI Optiv AI software, facilitating international expansion.
-
The company has a strong cash position with $40.8 million in cash and cash equivalents, providing a healthy runway into 2028.
-
Enrollment in the contrast PMR study has surpassed 50% of the target, supporting potential FDA submission by the end of 2026.
Negative Points
-
Despite revenue growth, Hyperfine Inc ( NASDAQ:HYPR ) reported a net loss of $8.6 million for Q1 2026.
-
The company's R&D expenses decreased by 24%, which may impact future innovation and development.
-
Sales, general, and administrative expenses remained flat, indicating potential challenges in cost management.
-
The company faces longer sales cycles with IDN opportunities, which could delay revenue realization.
-
Hyperfine Inc ( NASDAQ:HYPR ) continues to experience high cash burn, with $8.8 million burned in Q1 2026, despite efforts to reduce it.
Q & A Highlights
Q: Can you discuss the decision criteria and timelines for Integrated Delivery Networks (IDNs) and how many are at the standardization stage versus single-site pilots? A: Maria Sainz, CEO: We've had the next-generation subsystem for three quarters, and our IDN strategy is about three-quarters deep. One IDN has moved from a single site to multiple sites. The process involves regional or national approvals, and once the first system is implemented, it takes about two to three months of data collection before other sites move forward. We have visibility to multiple sites within an IDN, but procurement processes start after initial data collection. Brett Hale, CFO, added that the 2026 guidance reflects growth across hospital, office, and international business, with IDN initiatives aligning with budgetary cycles in the second half of the year.
Q: What is the profile of adopters in the office segment, and what signals have you seen from larger offices? A: Maria Sainz, CEO: We are predominantly placing the second-generation system in larger offices, often grouped under organizations like NeuroNet. These larger offices see the utility of the SEWP system across their patients, making it easier to justify the investment. Single practitioner practices have lower volumes and resources, so larger offices are more likely to find the investment attractive. Brett Hale, CFO, agreed with this assessment.
Q: How has the helium shortage in the U.S. impacted your interactions with potential customers? A: Maria Sainz, CEO: Our system does not require helium, which is a key selling point. We emphasize that our system is maintenance-light and helium-free. While helium shortages have been in the news, we haven't heard much directly from customers about it. Brett Hale, CFO, added that being helium-free and portable are elements they've highlighted, and recent news amplifies this advantage.
Q: What are the key economic factors you highlight when selling the SWOOP system to new customers, particularly in stroke care? A: Maria Sainz, CEO: The key data point is the wait time for MRI in stroke-suspected patients, which can be very high with high-field MRIs. Reducing this wait time builds a strong economic case for faster triage in the ED. In the ICU, the focus is on cost savings from reduced need for MRI-compatible supplies. These factors contribute to a one to one-and-a-half-year ROI, even with the current MSRP of $590,000.
Q: How will the gadolinium contrast impact adoption in hospital and office channels, and are purchases being delayed for this indication? A: Maria Sainz, CEO: There hasn't been a case where hospital purchases are delayed for contrast. There's excitement for contrast use in both hospital and office settings, as it represents a substantial number of scans. The increased utility will make multiple systems more necessary, and in offices, higher reimbursement rates for contrast cases will improve the economic calculation for adoption.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
